Expanded network of inflammatory markers of atherogenesis: Where are we now?

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 38-44

  Abbasi, Seyed Hesameddin ^a,b   Boroumand, Mohammad Ali ^b  

^a NATIONAL IRANIAN OIL COMPANY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atherosclerosis; C reactive protein; Cytokines; Inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CXCR2; FIBRINOGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; SMOOTH MUSCLE FIBER; T LYMPHOCYTE;

EID: 78249242112     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010038     Document Type: Article

References (132)

1. Sherer Y, Shoenfeld Y. Atherosclerosis. Ann Rheum Dis 2002; 61: 97-99.
2. Li JJ. Inflammation: an important mechanism for different clinical entities of coronary artery diseases. Chin Med J (Engl) 2005; 118: 1817-1826.
3. Li JJ, Nie SP, Xu B, Guo YL, Gao Z, Zheng X. Inflammation in variant angina: is there any evidence? Med Hypotheses 2007; 68: 635-640.
4. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavas-siliou VG. Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg 2006; 31: 386-393.
5. Ross R. Atherosclerosisan inflammatory disease. N Eng J Med 1999; 340: 115-126.
6. Rodríguez G, Mago N, Rosa F. Role of inflammation in athero-genesis. Invest Clin 2009; 50: 109-129.
7. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005; 3: 63-68.
8. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dys-function and vascular disease. Biochem Pharmacol 2009 15; 78: 539-552.
9. Zairis MN, Adamopoulou EN, Manousakis SJ, et al. Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators Biomarkers of Inflammation and Outcome in acute coronary Syndromes (BIAS) investigators. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 2007; 194: 397-402.
10. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006; 37: 1923-1932.
11. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003; 10: 63-71.
12. Tohidi M, Hadaegh F, Harati H, Azizi F. C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Int J Cardiol 2009; 132: 369-374.
13. Niccoli G, Biasucci LM, Biscione C, et al. Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. Atherosclerosis 2008; 196: 779-785.
14. Zhang SZ, Jin YP, Qin GM, Wang JH. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-st elevation acute coronary syndromes. Clin Cardiol 2007; 30: 26-31.
15. Sanchez PL, Morinigo JL, Pabon P, et al. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. Heart 2004; 90: 264-269.
16. Arena R, Arrowood JA, Fei DY, Helm S, Kraft KA. The relation-ship between C-reactive protein and other cardiovascular risk factors in men and women. J Cardiopulm Rehabil 2006; 26: 323-327.
17. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9: 471-474.
18. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol 1998; 9: 441-448.
19. Dichtl W, Nilsson L, Goncalves I, et al. Very low-density lipopro-tein activates nuclear factor-κB in endothelial cells. Circ Res 1999; 84: 1085-1094.
20. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coro-nary heart disease. Curr Opin Lipidol 1998; 9: 319-324.
21. Libby P. Inflammation: a common pathway in cardiovascular diseases. Dialog Cardiovasc Med 2003; 8: 59-73.
22. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497.
23. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
24. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-γ potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-2761.
25. Elhage R, Jawien J, Rudling M, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardio-vasc Res 2003; 59: 234-240.
26. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-γ and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol 2005; 25: 791-796.
27. Harris GD, White RD. Lifestyle modifications for the prevention and treatment of cardiovascular disease: an evidence-based approach. Mol Med 2004; 101: 222-226.
28. Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with endstage renal disease. Nephrol Dial Transplant 2004; 19: 67-72.
29. Maradit-Kremers H, Crowson CS, Nicola PJ. Increased unrecog-nized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheum 2005; 52: 402-411.
30. Shovman O, Gilburd B, Shoenfeld Y. The role of inflammatory cytokines in the pathogenesis of systemic Lupus erythematosus-re-lated atherosclerosis: a novel target for treatment. J Rheumatol 2006; 33: 445-447.
31. Deliargyris EN, Madianos PN, Kadoma W, et al. Periodontal disease in patients with acute myocardial infarction: prevalence and contribution to elevated C-reactive protein levels. Am Heart J 2004; 147: 1005-1009.
32. Gasparyan AY, Ugurlucan M. The emerging issue of cardiovascu-lar involvement in familial Mediterranean fever. Arch Med Sci 2008; 4: 465-467.
33. Saijo Y, Utsugi M, Yoshioka E, et al. Inflammation as a cardiovascular risk factor and pulse wave velocity as a marker of early-stage atherosclerosis in the Japanese population. Environ Health Prev Med 2009; 14:159-164.
34. Qamirani E, Ren Y, Kuo L, Hein TW. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arteri-oles by activating p38 kinase and NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2005; 25: 995-1001.
35. Boroumand MA, Sotoudeh AM, Sheikhvatan M, Saadat S, Abbasi SH, Sheikhfathollahi M. Do C-reactive protein and lipoprotein (a) have different impacts on the severity of coronary artery disease in diabetic and non-diabetic patients? J Tehran Univ Heart Cent 2008; 3: 163-168.
36. Sabatine MS, Morrow DA, Jablonski KA, et al. PEACE investiga-tors. Prognostic significance of the centers for disease control/ American heart association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115: 1528-1536.
37. Calabrò P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol 2009; 31: 79-94.
38. Bisoendial RJ, Birjmohun RS, Akdim F, et al. C-reactive protein elicits white blood cell activation in humans. Am J Med 2009; 122: 582-589.
39. Van Der Meer IM, De Maat MP, Hak AE, et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam study. Stroke 2002; 33: 2750-2755.
40. Bard RL, Clarke N, Rubenfire M, Eagle K, Brook RD. P-594: cardiovascular risk stratification obtained by Framingham risk score and C-reactive protein measurement. Am J Hypertens 2005; 18: 224.
41. Imai K, Okura H, Kume T, et al. C-reactive protein predicts non-target lesion revascularization and cardiac events following percu-taneous coronary intervention in patients with angina pectoris. J Cardiol 2009; 53: 388-395.
42. García-Lorda P, Bulló M, Balanzà R, Salas-Salvadó J. C-reactive protein, adiposity and cardiovascular risk factors in a Mediterra-nean population. Int J Obes (Lond) 2006; 30: 468-474.
43. Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski JC. C-reactive protein predicts functional status and correlates with left ventricular ejection fraction in patients with chronic stable angina. Atherosclerosis 2009; 205: 319-324.
44. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112: 25-31.
45. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897-1908.
46. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995; 2: 197-205.
47. Andreotti F, Burzotta F, Maseri A. Fibrinogen as a marker of inflammation: a clinical view. Blood Coagul Fibrinol 1999; 10: 3-4.
48. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk fac-tors. Arterioscler Thromb Vasc Biol 1995; 15: 1263-1268.
49. Broadhurst P, Kelleher C, Hughes K, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990; 85: 169-173.
50. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick park heart study. Lancet 1986; 2: 533-537.
51. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease, the Framingham study. JAMA 1987; 258: 1186-1183.
52. Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The caerphilly and speedwell collaborative heart disease studies. Circulation 1991; 83: 836-844.
53. Sabeti S, Exner M, Mlekusch W, et al. Prognostic impact of fibrinogen in carotid atherosclerosis. Stroke 2005; 36: 1400-1404.
54. Green D, Foiles N, Chan C, Schreiner PJ, Liu K. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA study. Atherosclerosis 2009; 202: 623-631.
55. Best LG, North KE, Li X, et al. Linkage study of fibrinogen levels: the strong heart family study. BMC Med Genet 2008; 9: 77.
56. Sie MP, Isaacs A, de Maat MP, et al. Genetic variation in the fibrinogen-alpha and fibrinogen-gamma genes in relation to arterial stiffness: the Rotterdam study. J Hypertens 2009; 27: 1392-1398.
57. Song C, Shen Y, Yamen E, et al. Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syn-dromes. Atherosclerosis 2009; 202: 596-604.
58. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol 2009; 53: 317-333.
59. Lei X, Buja LM. Detection and localization of tumor necrosis factor-α in WHHL rabbit arteries. Atherosclerosis 1996; 125: 81-89.
60. Gotsman I, Stabholz A, Planer D, et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J 2008; 10: 494-498.
61. Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-α-reduces athero-sclerosis in apolipoprotein e knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 2137-2142.
62. Boesten LS, Zadelaar AS, van Nieuwkoop A, et al. Tumor necrosis factor-α promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardiovasc Res 2005; 66: 179-185.
63. Bruunsgaard H, Skinhøj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumor necrosis factor-α (TNF-α) and atherosclerosis. Clin Exp Immunol 2008; 121: 255-260.
64. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-3067.
65. Taniguchi A, Fukushima M, Nakai Y, et al. Soluble tumor necrosis factor receptor 1 is strongly and independently associated with serum homocysteine in nonobese japanese type 2 diabetic patients. Diabetes Care 2006; 29: 949-950.
66. Taub DD, Proost P, Murphy WJ, et al. Monocyte chemotactic protein-1 (MCP-1),-2, and-3 are chemotactic for human T lym-phocytes. J Clin Invest 1995; 95: 1370-1376.
67. Lu Y, Cai Z, Galson DL, et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006; 66: 1311-1318.
68. Gosling J, Slaymaker S, Gu L, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999; 103: 773-778.
69. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion forma-tion in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897.
70. Chikaraishi A, Hirahashi J, Takase O, et al. Tranilast inhibits interleukin-1beta-induced monocyte chemoattractant protein-1 expression in rat mesangial cells. Eur J Pharmacol 2001; 427: 151-158.
71. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascu-lar functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25: 9-12.
72. Chen YL, Chang YJ, Jiang MJ. Monocyte chemotactic protein-1 gene and protein expression in atherogenesis of hypercholes-terolemic rabbits. Atherosclerosis 1999; 143: 115-123.
73. Ni W, Kitamoto S, Ishibashi M, et al. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholes-terolemic mice. Arterioscler Thromb Vasc Biol 2004; 24: 534-539.
74. Gotsman I, Stabholz A, Planer D, et al. Serum cytokine tumor necrosis factor-α and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory bur-den? Isr Med Assoc J 2008; 10: 494-498.
75. Rott D, Zhu J, Fu Zhou Y, Burnett MS, Zalles-Ganley A, Epstein SE. IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. Atherosclerosis 2003; 170: 223-228.
76. Amar J, Fauvel J, Drouet L, et al. Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhe-sion molecule 1. J Hypertens 2006; 24: 1083-1088.
77. Saremi A, Anderson RJ, Luo P, et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis 2009; 203: 610-614.
78. Huber SA. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999; 19: 2364-7.
79. Abeywardena MY, Leifert WR, Warnes KE, Varghese JN, Head RJ. Cardiovascular biology of interleukin-6. Curr Pharm Des 2009; 15: 1809-1821.
80. Haddya N, Sassa C, Droescha S, et al. IL-6, TNF-α and atheroscle-rosis risk indicators in a healthy family population: the STANIS-LAS cohort. Atherosclerosis 2003; 170: 277-283.
81. Simonini A, Moscucci M, Muller DW, et al. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation 2000; 101: 1519-1526.
82. Boisvert WA, Curnss LK, Terkeltaub RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000; 21: 129-137.
83. Boekholdt SM, Peters RJ, Hack CE, et al. IL-8 plasma concentra-tions and the risk of future coronary artery disease in apparently healthy men and women. Arterioscler Thromb Vasc Biol 2004; 24: 1503-1508.
84. Hirokazu K, Tamikazu N, Yasuhiro Y, et al. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 656-660.
85. Merhi-Soussia F, Kwakc BR, Magnea D, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 2005; 66: 583-593.
86. King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/-mice. Arterioscler Thromb Vasc Biol 2002; 22: 456-461.
87. Cornicellia JA, Butteigerb D, Raterib DL, Welcha K, Daugherty A. Interleukin-4 augments acetylated LDL-induced cholesterol esteri-fication in macrophages. J Lipid Res 2000; 41: 376-383.
88. Kahraman S, Yilmaz R, Arici M, et al. IL-10 genotype predicts serum levels of adhesion molecules, inflammation and atheroscle-rosis in hemodialysis patients. J Nephrol 2006; 19: 50-56.
89. Lakoskia SJ, Liub Y, Bridget Brosnihanc K, Herrington DM. Inter-leukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study. Atherosclerosis 2008; 197: 443-447.
90. Mallat Z, Heymes C, Ohan J, Faggin E, Lesèche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to induci. Arterioscler Thromb Vasc Biol 1999; 19: 611-616.
91. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circulation Res 1999; 85: 17-24.
92. Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 734-742.
93. Zhang X, Niessner A, Nakajima T, et al. Interleukin 12 Induces T-cell recruitment into the atherosclerotic plaque. Circ Res 2006; 98: 434-6.
94. Masaharu K, Mitsuru O, Norihisa I, et al. Serum interleukin-15 concentration in patients with essential hypertension. Am J Hyper-tens 2005; 18: 1019-1025.
95. Wuttge DM, Eriksson P, Sirsjö A, Hansson GK, Stemme S. Expression of interleukin-15 in mouse and human atherosclerotic lesions. Am J Pathol 2001; 159: 417-423.
96. Houtkamp MA, van der Wal AC, de Boer OJ, et al. Interleukin-15 expression in atherosclerotic plaques an alternative pathway for T-cell activation in atherosclerosis? Arterioscler Thromb Vasc Biol 2001; 21:1208-1213.
97. Nakamura A, Shikata K, Hiramatsu M, et al. Serum Interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005; 28: 2890-2895.
98. Mallat Z, Corbaz A, Scoazec A, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion devel-opment and stability. Circ Res 2001; 89: 41-45.
99. Yearley JH, Xia D, Pearson GB, Carville A, Shannon RP, Mans-field KG. Interleukin-18 predicts atherosclerosis progression in SIV-infected and uninfected rhesus monkeys (Macaca mulatta) on a high-fat/high-cholesterol diet. Lab Invest 2009; 89: 657-667.
100. Elhage R, Jawien J, Rudling M, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardio-vasc Res 2003; 59: 234-240.
101. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-γ and CXCL16 expression independently of T-cells. Arterioscler Thromb Vasc Biol 2005; 25:791-799.
102. Castellani ML, Kempuraj DJ, Salini V, et al. The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator. J Biol Regul Homeost Agents 2009; 23: 11-14.
103. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the develop-ment of atherosclerosis. J Exp Med 2007; 205: 339-346.
104. Kitagawa K, Matsumoto M, Sasaki T, et al. Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. Atherosclerosis 2002; 160: 305-310.
105. Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009; 61: 22-32.
106. Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhe-sion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999; 85: 199-207.
107. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18: 842-851.
108. Rohde LK, Lee RT, Rivero J, et al. Circulating cell adhesion mole-cules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998;18: 1765-1770.
109. Ridker PM, Hennekens CH, Ritman-Johnson B, Stamper MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
110. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis J Clin Invest 2001; 107: 1209-1210.
111. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1-4.
112. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomark-ers in acute coronary syndromes: part IV: matrix metalloprotein-ases and biomarkers of platelet activation. Circulation 2006; 113: 382-385.
113. Galis Z, Khatri J. Matrix metalloproteinases in vascular modeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2003; 90: 251-262.
114. Creemers E, Cleutjens J, Smits J, Daemen M. Matrix metalloprote-inase inhibition after myocardial infarction: a new approach to pre-vent heart failure? Circ Res 2001; 89: 201-210.
115. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulner-able regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
116. Eckart R, Uyehara C, Shry E, Furgerson J, Krasuski R. Matrix metalloproteinases in patients with myocardial infarction and per-cutaneous revascularization. J Interv Cardiol 2004; 17: 27-31.
117. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardio-vascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843.
118. Ridker PM, Hennekens CH, Buring JE. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
119. Hwang SJ, Ballantyne CM, Sharrett AR. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atheroscle-rosis and incident coronary heart disease cases. The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96: 4219-4225.
120. Danesh J, Whincup P, Walker M. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
121. Pearson TA, Mensah GA, Alexander RW, et al. Centers for disease control and prevention; American heart association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American heart association. Circulation 2003; 107: 499-511.
122. Meier-Ewert HK, Ridker PM, Rifai N. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001; 47: 426-430.
123. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-2141.
124. Ridker PM. Clinical application of C-reactive protein for cardio-vascular disease detection and prevention. Circulation 2003; 107: 363-9.
125. Ridker PM, Rifai N, Rose L. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
126. Ridker PM, Buring JE, Cook NR. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
127. Fiotti N, Di Chiara A, Altamura N, et al. Coagulation indicators in chronic stable effort angina and unstable angina: relationship with acute phase reactants and clinical outcome. Blood Coagul Fibrinol-ysis 2002; 13: 247-255.
128. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. C-reactive protein in patients with acute coronary syndrome: corre-lation with diagnosis, myocardial damage, ejection fraction and an-giographic findings. Int J Cardiol 2006; 109: 248-256.
129. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syn-drome treated with a very early invasive strategy in 1042 consecu-tive patients. Circulation 2002; 105: 1412-1415.
130. Kim H, Yang DH, Park Y, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J 2006; 70: 1379-1384.
131. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol 2006; 1: 297-329.
132. Moubayed SP, Heinonen TM, Tardif JC. Anti-inflammatory drugs and atherosclerosis. Curr Opin Lipidol 2007; 18: 638-644.